Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Gallium PSMA-PET/CT in Metastatic Urothelial Carcinoma or Melanoma
NCT05562791Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2022
- Primary completion
- Sep 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of gallium ga-68 gozetotide in urothelial carcinoma (UC) and melanoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Proportion of patients with 1 or more lesions detectable by 68Gallium PSMA-PET/CT for Urothelial Carcinoma at 1 year and Proportion of patients with 1 or more lesions detectable by 68Gallium PSMA-PET/CT for Melanoma at 1 year. Started Sep 2022; status: recruiting.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
urothelial carcinoma (UC)melanoma
Beyond the preview
Go deeper on NCT05562791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562791.